Beam Therapeutics Inc. (NASDAQ:BEAM) Receives $49.00 Consensus PT from Analysts

Beam Therapeutics Inc. (NASDAQ:BEAM) has been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $49.00.

A number of research firms have recently weighed in on BEAM. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Beam Therapeutics in a research report on Tuesday, August 25th. Bank of America reiterated a “buy” rating and issued a $47.00 target price on shares of Beam Therapeutics in a report on Wednesday, July 8th. Wall Street Zen cut Beam Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday. Wedbush restated an “outperform” rating and set a $65.00 price target on shares of Beam Therapeutics in a report on Wednesday, September 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Friday, July 17th.

Beam Therapeutics Stock Performance

Shares of BEAM stock opened at $23.99 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.57 and a current ratio of 14.57. The stock has a market capitalization of $2.48 billion, a P/E ratio of -27.90 and a beta of 2.22. The company has a 50 day moving average price of $28.50 and a 200 day moving average price of $28.89. Beam Therapeutics has a fifty-two week low of $20.23 and a fifty-two week high of $38.26.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.07). Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%.The business had revenue of $0.49 million for the quarter, compared to analysts’ expectations of $16.37 million. During the same period in the previous year, the company earned ($1.00) earnings per share. Beam Therapeutics’s quarterly revenue was down 94.2% on a year-over-year basis. Equities research analysts predict that Beam Therapeutics will post -4.49 EPS for the current fiscal year.

Beam Therapeutics News Roundup

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Analysts maintain bullish views. Wedbush reaffirmed its Buy/Outperform rating, while Canaccord Genuity and JonesTrading also maintained Buy ratings. Separately, the brokerage consensus remains “Moderate Buy,” supporting investor confidence in Beam’s pipeline and long-term prospects. Wedbush Reaffirms Their Buy Rating Wedbush Reiterates Outperform Rating Consensus Moderate Buy Rating
• Positive Sentiment: BEAM-302 data show sustained biomarker improvement. Updated Phase 1/2 results in alpha-1 antitrypsin deficiency indicated that the investigational treatment restored AAT levels, with biomarker follow-up extending to 18 months. The results strengthen the case for continued development, although the study remains early stage and clinical benefit has not yet been conclusively established. BEAM-302 Clinical Data Analysis
• Neutral Sentiment: Options activity increased. Unusually large options trading was reported, which may signal heightened speculation or hedging but does not establish a clear directional outlook for BEAM. Unusually Large Options Trading
• Neutral Sentiment: Reports of a sharp increase in short interest showed zero shares both before and after the period, suggesting a data-quality issue rather than a meaningful change in bearish positioning.
• Negative Sentiment: Pomerantz LLP is investigating potential investor claims. The law firm’s announcement may add legal and headline risk, although it does not allege that Beam has been found liable. Pomerantz Investor Investigation

Insider Transactions at Beam Therapeutics

In other news, insider Fmr Llc sold 251,488 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the completion of the transaction, the insider directly owned 854,583 shares of the company’s stock, valued at approximately $30,132,596.58. The trade was a 22.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Amy Simon sold 16,667 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $25.74, for a total transaction of $429,008.58. Following the sale, the insider owned 85,696 shares in the company, valued at $2,205,815.04. The trade was a 16.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 301,527 shares of company stock valued at $10,468,500. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

Large investors have recently modified their holdings of the company. Hollencrest Capital Management acquired a new stake in shares of Beam Therapeutics in the 1st quarter valued at $43,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Beam Therapeutics during the second quarter worth $43,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Beam Therapeutics during the fourth quarter worth $47,000. Larson Financial Group LLC increased its holdings in Beam Therapeutics by 4,370.5% in the third quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock valued at $48,000 after buying an additional 1,923 shares during the last quarter. Finally, Van ECK Associates Corp increased its holdings in Beam Therapeutics by 48.7% in the third quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock valued at $52,000 after buying an additional 707 shares during the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source.

The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers.